|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9312
|
|
pubmed:dateCreated |
2002-4-10
|
|
pubmed:abstractText |
Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p<0 small middle dot0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:BakerKatherine LKL,
pubmed-author:BowmanCliveC,
pubmed-author:DaviesKirstieK,
pubmed-author:DowDavid JDJ,
pubmed-author:HandleyAbigailA,
pubmed-author:HetheringtonSethS,
pubmed-author:HughesArlene RAR,
pubmed-author:LaiEricE,
pubmed-author:MostellerMichaelM,
pubmed-author:OmastaAA,
pubmed-author:RosesAllen DAD,
pubmed-author:ShortinoDeniseD,
pubmed-author:SpreenWilliamW,
pubmed-author:StocumMichaelM,
pubmed-author:ThurmondLinda MLM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
30
|
|
pubmed:volume |
359
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1121-2
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11943262-Adult,
pubmed-meshheading:11943262-Aged,
pubmed-meshheading:11943262-Anti-HIV Agents,
pubmed-meshheading:11943262-Case-Control Studies,
pubmed-meshheading:11943262-Continental Population Groups,
pubmed-meshheading:11943262-Dideoxynucleosides,
pubmed-meshheading:11943262-Drug Hypersensitivity,
pubmed-meshheading:11943262-Female,
pubmed-meshheading:11943262-Genetic Markers,
pubmed-meshheading:11943262-Genetic Variation,
pubmed-meshheading:11943262-HIV Infections,
pubmed-meshheading:11943262-HIV-1,
pubmed-meshheading:11943262-HLA-B Antigens,
pubmed-meshheading:11943262-Humans,
pubmed-meshheading:11943262-Male,
pubmed-meshheading:11943262-Middle Aged,
pubmed-meshheading:11943262-Polymorphism, Genetic,
pubmed-meshheading:11943262-Predictive Value of Tests,
pubmed-meshheading:11943262-Retrospective Studies,
pubmed-meshheading:11943262-Reverse Transcriptase Inhibitors,
pubmed-meshheading:11943262-Sensitivity and Specificity,
pubmed-meshheading:11943262-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
|
|
pubmed:affiliation |
HIV Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. svh31379@gsk.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
